Related Experiment Video
Updated: Jul 10, 2025

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Relation Between Calcium-Phosphorus Product and Total Coronary Artery Occlusion in a Nonchronic Kidney Disease
Kaiyong Xiao1, Huili Cao2, Liang Liu1
1The Second Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China.
Insights
A higher calcium-phosphorus product (Ca-P product) in individuals without chronic kidney disease (CKD) is linked to a reduced risk of total coronary artery occlusion (TCAO). Maintaining a Ca-P product below 27.46 mg²/dl² may help prevent TCAO.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Biochemistry
Background:
- Elevated calcium-phosphorus product (Ca-P product) is linked to cardiovascular issues in chronic kidney disease (CKD) patients.
- The association between Ca-P product and coronary artery disease in non-CKD populations remains under-investigated.
Purpose of the Study:
- To investigate the role of Ca-P product in total coronary artery occlusion (TCAO) within a non-CKD population.
- To determine the threshold of Ca-P product associated with TCAO risk in this demographic.
Main Methods:
- A cross-sectional study involving 983 patients undergoing coronary angiography.
- Ca-P product calculated and analyzed as a continuous and tertiary variable.
- Logistic regression and restricted cubic splines used for statistical analysis.
Main Results:
- A significant inverse association was found between Ca-P product and TCAO risk (OR 0.96 per unit increase).
- Higher Ca-P product groups showed a 40% reduced risk of TCAO compared to the lowest group.
- A nonlinear relationship was observed, with TCAO risk decreasing significantly after a Ca-P product of 27.46 mg²/dl².
Conclusions:
- In non-CKD populations, a higher Ca-P product (≥27.46 mg²/dl²) is associated with a lower risk of TCAO.
- This finding suggests a potential protective role of elevated Ca-P product against complete coronary artery occlusion in individuals without kidney disease.
Abstract:
Excessive calcium-phosphorus product (Ca-P product) in patients with chronic kidney disease (CKD) is associated with coronary artery calcification and coronary artery disease, but the relation between Ca-P product and coronary artery disease in non-CKD populations has rarely been reported. Therefore, we designed a cross-sectional study to investigate the role of Ca-P product in total coronary artery occlusion (TCAO) in a non-CKD population. We reviewed 983 patients who underwent coronary angiography at Guangyuan Central Hospital from February 2018 to January 2020. Ca-P product (mg2/dl2) was calculated as Ca (mmol/L) × 4 × P (mmol/L) × 3.1 and was analyzed as a continuous and tertiary variable. TCAO was defined as complete occlusion of any coronary artery by coronary angiography (thrombolysis in myocardial infarction flow grade 0). Statistical analysis was performed using univariate and multivariate logistic regression models and restricted cubic splines. Univariate logistic regression analysis showed a statistically significant association between Ca-P product and TCAO (odds ratio [OR] 0.97, 95% confidence interval [CI] 0.95 to 0.99, p <0.001). After stepwise adjustment for covariates, the risk of TCAO was reduced by 40% in the high versus low Ca-P group (OR 0.6, 95% CI 0.38 to 0.95, p = 0.031), and the risk of TCAO was predicted to decrease by 4% (OR 0.96, 95% CI 0.94 to 0.99, p = 0.006) for each unit increase in Ca-P product. Restricted cubic splines showed a nonlinear relation between Ca-P product and TCAO, with a significant decrease in the risk of TCAO after reaching 27.46 (nonlinear p = 0.047). In conclusion, in non-CKD populations, a higher Ca-P product (≥27.46 mg2/dl2) may help avoid TCAO.
Related Concept Videos
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology

